SERES THERAPEUTICS INC (MCRB)
US81750R1023 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to MCRB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.36. This target is 534.86% above the current price.
MCRB was analyzed by 13 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about MCRB.
In the previous month the buy percentage consensus was at a similar level.
MCRB was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-03-06 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-03-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-01-16 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-11-03 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-04-28 | Chardan Capital | Maintains | Buy |
| 2023-04-21 | JP Morgan | Initiate | Neutral |
| 2023-03-21 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | Chardan Capital | Reiterate | Buy |
| 2023-03-08 | Canaccord Genuity | Maintains | Buy |
| 2023-03-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-08 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-07 | Piper Sandler | Maintains | Overweight |
| 2022-05-23 | Piper Sandler | Maintains | Overweight |
| 2021-07-23 | Chardan Capital | Maintains | Buy |
| 2021-07-23 | Oppenheimer | Maintains | Outperform |
| 2021-07-23 | Canaccord Genuity | Maintains | Buy |
| 2021-07-23 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2021-07-23 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-05 | HC Wainwright & Co. | Maintains | Buy |
| 2021-03-05 | Chardan Capital | Upgrade | Neutral -> Buy |